A Multicenter, Double Blind, Vehicle-controlled, Randomized Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream and Aktilite CL128 LED Light in Patients With Multiple Actinic Keratosis on the Face and/or Scalp

ClinicalTrials.gov processed this data on August 3, 2022. Link to the current ClinicalTrials.gov record.

Recruitment Status

COMPLETED - HAS RESULTS
 (See Contacts and Locations)
Verified August 2022 by Galderma R&D

Sponsor

Galderma R&D

Information Provided by (Responsible Party)

Galderma R&D

Clinicaltrials.gov Identifier

NCT00304239
Other Study ID Numbers: PC T405/05
First Submitted: March 16, 2006
First Posted: March 17, 2006
Results First Posted: July 3, 2023
Last Update Posted: July 3, 2023
Last Verified: August 2022
History of Changes

Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.

ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.

Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.

Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.

For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.

See also the Web Policies and Notices for the NIH web site.

Study Description

Actinic keratoses are pre-malignant skin lesions, which may develop to squamous cell carcinomas (SCC). They are usually small, thin, erythematous, de-squamating lesions on light exposed atrophic skin and the lesions are often multiple.

Photodynamic therapy (PDT) is the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulate more photosensitiser than normal cells. The photosensitiser generates reactive oxygen species upon illumination.

For skin diseases, such as actinic keratosis (AK), there has been an increasing interest in using topically applied precursors of the photoactive porphyrins (PAP). The most commonly used precursors have been 5-aminolevulinic acid (ALA) and its derivatives. The present test drug contains methyl aminolevulinate, which penetrates the lesions well and shows high lesion selectivity.

Different light sources (i.e. CureLight, Aktilite CL16 and Aktilite CL128) had been used for the activation of PAP, which absorbs light in the range of 400-700 nanometer (nm). The present study used the Aktilite CL 128 lamp. Aktilite 128 was based on LED technology and emits a narrow red light spectrum with an average wavelength of 630 (+/-5) nm. This study was similar to two other studies performed, on which the U.S. approval of Metvixia cream was based except for the light source used. This study was one of two studies performed to document the safety and efficacy of the Aktilite CL 128 lamp when used in combination with Metvixia cream.

Previous studies have shown that the risks attributed to Metvixia PDT are few and related mainly to transient pain and local erythema during and shortly after treatment. These reactions are part of the expected local phototoxicity reaction. PDT offers an advantage to other treatment modalities for actinic keratosis, being a non-invasive treatment available on an outpatient basis. Several separate lesions can be treated simultaneously and the same lesion(s) can be treated repeatedly with success. There are no known systemic toxicity or interaction with other medication. The treatment is also lesion selective, leaving the surrounding tissue intact and functional, also allowing excellent cosmetic results after treatment.
Condition or Disease Intervention/Treatment
  • Actinic Keratosis
  • Combination Product: Metvix-PDT
  • Combination Product: Vehicle-PDT

Study Design

Study TypeInterventional
Actual Enrollment131 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingDouble
Primary PurposeTreatment
Official TitleA Multicenter, Double Blind, Vehicle-controlled, Randomized Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream and Aktilite CL128 LED Light in Patients With Multiple Actinic Keratosis on the Face and/or Scalp
Study Start DateMarch 13, 2006
Actual Primary Completion DateJanuary 23, 2007
Actual Study Completion DateJanuary 23, 2007

Groups and Cohorts

Group/ CohortIntervention/ Treatment
  • Metvix-PDT
    • Participants received Metvix-PDT (methyl aminolevulinate hydrochloride-Photodynamic therapy) 160 milligrams per gram (mg/g) cream on face and/or scalp for 3 hours on Day 0 and Day 7.
  • Combination Product: Metvix-PDT
    • Metvix 160 mg/g Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 Joule/square centimeter (J/cm²). All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
  • Vehicle-PDT
    • Participants received Vehicle cream (Vehicle-PDT) on face and/or scalp for 3 hours on Day 0 and Day 7.
  • Combination Product: Vehicle-PDT

    Outcome Measures

    Primary Outcome Measures

    1. Participant Complete Response Rate (CRR) [At Week 13]
      Participant complete response rate was defined as the percentage of participants with complete response. Complete response was defined as the complete disappearance of the lesion determined by clinical assessment (visual inspection and palpation) by an investigator.

    Secondary Outcome Measures

    1. Lesion Complete Response Rate [At Week 13]
      Lesion complete response rate was defined as the percentage of pre-existing and treated lesions at baseline that were assessed as clear (complete disappearance of the lesion, visually and by palpation) after treatment. Percentage of lesions reported by location.
    2. Number of Participants With at Least One Treatment Site Adverse Events [From start of study drug administration up to Week 13]
      An AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily had a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Number of participants with at least one treatment site adverse events were reported.

    Eligibility Criteria

    Ages Eligible for Study 18 Years and Older (Adult, Older Adult)
    Sexes Eligible for Study All
    Accepts Healthy Volunteers No
    Inclusion Criteria
    • Clinical diagnosis of 4-10 previously untreated, not pigmented, non-hyperkeratotic AK lesions of 3 mm or more diameter of Grade 1 and/or 2 of the face and/or scalp where other therapies are unacceptable or considered medically less appropriate.
    • Males or females above 18 years of age.
    • Written informed consent.
    Exclusion Criteria
    • Participants with porphyria.
    • Participants immunosuppressed for idiopathic, disease specific or therapeutic reasons.
    • Known allergy to MAL, a similar PDT compound or excipients of the cream.
    • Participants with history of hypersensitivity to nut products or other known protein antigens.
    • Participation in other clinical studies either currently or within the last 30 days.
    • Participants receiving local treatment (including cryotherapy and curretage) in face / scalp area within the last 30 days.
    • Participants receiving topical treatment (including imiquimod, 5-FU and diclofenac) in face / scalp area within the last 3 months.
    • Pregnant or breast-feeding: All women of child-bearing potential must use adequate contraception (oral contraceptives, intrauterine device, contraceptive skin patch, etc) during the treatment period and one month thereafter. In addition, they must have a negative pregnancy test prior to treatment.
    • Any conditions that may be associated with a risk of poor protocol compliance.
    • Participants currently receiving regular ultraviolet radiation therapy.

    Contacts and Locations

    Sponsors and Collaborators Galderma R&D
    Locations
    • Ashish C. Bhatia | Naperville, Illinois, United States, 60563
    • Joseph Fowler | Louisville, Kentucky, United States, 40202
    • Robert T. Matheson | Portland, Oregon, United States, 97223
    • Steven A. Davis | San Antonio, Texas, United States, 78229
    • Hautklinik Heinrich Heine Universität | Dusseldorf, Germany, 40223
    • Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main | Frankfurt, Germany, 60590
    • Praxis Dr. Winfried Klövekorn | Gilching, Germany, 82205
    • Klinik für Dermatologie und Venerologie Universitätsklinikum Schleswig-Holstein, Campus Lübeck | Lubeck, Germany, 23538
    • Klinikum der Universität München, Klinikum und Poliklinik für Dermatologie und Allergologie | Munchen, Germany, 80337
    • Klinik und Poliklinik für Dermatologie, Klinikum der Universität Regensburg | Regensburg, Germany, 93053
    • Praxis Dr. Klemm | Tutzing, Germany, 82327
    Investigators
    • Principal Investigator: Rolf M Szeimies, Professor, Klinik und Poliklinik für Dermatologie, Klinikum der Universität Regensburg